Related Experiment Video
Updated: May 20, 2026
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Monoclonal antibodies: from benchtop to bedside
1Office of Clinical Pharmacology, Center for Drug Evaluation & Research, US FDA, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. jane.bai@fda.hhs.gov
Therapeutic Delivery
|July 27, 2012
Summary
Monoclonal antibodies offer vast medical potential, with advancements in delivery technologies continuously expanding their therapeutic applications. Future innovations promise to unlock even broader benefits for patients.
Area of Science:
- Biotechnology
- Immunology
- Drug Delivery Systems
Background:
- Monoclonal antibodies (mAbs) represent a significant class of therapeutics with diverse applications.
- Their clinical utility is currently constrained by delivery methods and technological limitations.
Purpose of the Study:
- To explore the expanding medical utility of monoclonal antibodies.
- To highlight the anticipated evolution of delivery strategies and technologies for mAbs.
Main Methods:
- This abstract does not detail specific methods.
- It focuses on conceptual advancements and future expectations in mAb delivery.
Main Results:
- The potential applications of monoclonal antibodies are vast and largely unexplored.
- Technological progress in delivery systems is crucial for realizing this potential.
Conclusions:
- The medical benefits of monoclonal antibodies are expected to grow significantly.
- Continued innovation in efficient and accurate delivery technologies is key to unlocking the full therapeutic promise of mAbs.
